Literature DB >> 17172852

Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".

Steven M Kornblau1, Yi Hua Qiu, B N Bekele, Jenny Straka Cade, Xian Zhou, David Harris, C Ellen Jackson, Zeev Estrov, Michael Andreeff.   

Abstract

We hypothesized that studying protein expression in cells surviving in vitro chemotherapy ("survivor cells", SV), could provide more important insight into the biology of drug-resistant AML cells than analysis of the bulk population of leukemic cells. Leukemia-enriched samples from 79 patients with new or relapsed AML were cultured for four days +/- cytarabine (5-10 microM). Early apoptotic cells were removed to yield purified SV. Expression of BCL2, bax, PKC alpha, ERK2 and pERK2 proteins was measured using laser scanning cytometry. The SV population was enriched for CD34+ stem cells. Protein expression patterns in SV differed considerably from those in controls; culture and reanalysis of protein expression revealed stability, reversion, or new patterns of change. Patterns of pairs or triads of proteins were nonrandomly distributed and appeared at statistically unlikely frequencies, suggesting preferential adoption of certain patterns. The patterns of change were highly predictive of remission attainment, relapse, and survival in univariate and multivariate analysis. We conclude that in vitro SV cells have protein expression patterns distinct from those of the bulk population of leukemic cells and that these patterns are predictive of outcome. Analysis of SV cells may be more informative than analysis of the bulk population of leukemia cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172852     DOI: 10.4161/cc.5.23.3507

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  6 in total

1.  Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy.

Authors:  Xinquan Lü; Qing Deng; Huixiang Li; Zhenhe Suo
Journal:  Exp Ther Med       Date:  2011-06-02       Impact factor: 2.447

2.  Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Authors:  Vivian R Ruvolo; Kul B Karanjeet; Todd F Schuster; Rhoderick Brown; Yibin Deng; Edward Hinchcliffe; Peter P Ruvolo
Journal:  J Signal Transduct       Date:  2010-01-01

3.  Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Authors:  C C Porter; J Kim; S Fosmire; C M Gearheart; A van Linden; D Baturin; V Zaberezhnyy; P R Patel; D Gao; A C Tan; J DeGregori
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

Review 4.  Targeting mTOR for the treatment of AML. New agents and new directions.

Authors:  Jessica K Altman; Antonella Sassano; Leonidas C Platanias
Journal:  Oncotarget       Date:  2011-06

5.  Tetraspanin CD82 Regulates the Spatiotemporal Dynamics of PKCα in Acute Myeloid Leukemia.

Authors:  Christina M Termini; Keith A Lidke; Jennifer M Gillette
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

Review 6.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.